304 related articles for article (PubMed ID: 26017288)
21. Diagnostic challenges in the work up of hypereosinophilia: pitfalls in bone marrow core biopsy interpretation.
Schwaab J; Jawhar M; Naumann N; Schmitt-Graeff A; Fabarius A; Horny HP; Cross NC; Hofmann WK; Reiter A; Metzgeroth G
Ann Hematol; 2016 Mar; 95(4):557-62. PubMed ID: 26797429
[TBL] [Abstract][Full Text] [Related]
22. Mast cells and eosinophils in mastocytosis, chronic eosinophilic leukemia, and non-clonal disorders.
Gotlib J; Akin C
Semin Hematol; 2012 Apr; 49(2):128-37. PubMed ID: 22449623
[TBL] [Abstract][Full Text] [Related]
23. [Studying of clinical and laboratory features of chronic eosinophilic leukemias /hypereosinophilic syndrome].
Zhang Y; Yu MH; Xu SC; Yang L; Yu Y; Hao YS; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):3-8. PubMed ID: 18512307
[TBL] [Abstract][Full Text] [Related]
24. Systemic mastocytosis is uncommon in KIT D816V mutation positive core-binding factor acute myeloid leukemia.
Kristensen T; Preiss B; Broesby-Olsen S; Vestergaard H; Friis L; Møller MB
Leuk Lymphoma; 2012 Jul; 53(7):1338-44. PubMed ID: 22145956
[TBL] [Abstract][Full Text] [Related]
25. Routine KIT p.D816V screening identifies clonal mast cell disease in patients with Hymenoptera allergy regularly missed using baseline tryptase levels alone.
Šelb J; Rijavec M; Eržen R; Zidarn M; Kopač P; Škerget M; Bajrović N; Luzar AD; Park YH; Liu Y; Šerbec VČ; Zver S; Košnik M; Lyons JJ; Korošec P
J Allergy Clin Immunol; 2021 Aug; 148(2):621-626.e7. PubMed ID: 33753098
[TBL] [Abstract][Full Text] [Related]
26. Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.
Tefferi A
J Cell Mol Med; 2009 Feb; 13(2):215-37. PubMed ID: 19175693
[TBL] [Abstract][Full Text] [Related]
27. Mutational Hotspot of TET2, IDH1, IDH2, SRSF2, SF3B1, KRAS, and NRAS from Human Systemic Mastocytosis Are Not Conserved in Canine Mast Cell Tumors.
Zorzan E; Hanssens K; Giantin M; Dacasto M; Dubreuil P
PLoS One; 2015; 10(11):e0142450. PubMed ID: 26562302
[TBL] [Abstract][Full Text] [Related]
28. Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis.
Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
Eur J Haematol; 2012 Jul; 89(1):42-6. PubMed ID: 22469616
[TBL] [Abstract][Full Text] [Related]
29. FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib.
Wang LN; Pan Q; Fu JF; Shi JY; Jin J; Li JM; Hu J; Zhao WL; Chen Z; Chen SJ
Chin Med J (Engl); 2008 May; 121(10):867-73. PubMed ID: 18706197
[TBL] [Abstract][Full Text] [Related]
30. Prospective evaluation of the diagnostic value of sensitive KIT D816V mutation analysis of blood in adults with suspected systemic mastocytosis.
Kristensen T; Vestergaard H; Bindslev-Jensen C; Mortz CG; Kjaer HF; Ollert M; Møller MB; Broesby-Olsen S;
Allergy; 2017 Nov; 72(11):1737-1743. PubMed ID: 28432683
[TBL] [Abstract][Full Text] [Related]
31. The impact of sensitive KIT D816V detection on recognition of indolent Systemic Mastocytosis.
De Matteis G; Zanotti R; Colarossi S; De Benedittis C; Garcia-Montero A; Bonifacio M; Sartori M; Aprili F; Caruso B; Paviati E; Carli G; Perbellini O; Zamò A; Bonadonna P; Pizzolo G; Guidi G; Martinelli G; Soverini S
Leuk Res; 2015 Mar; 39(3):273-8. PubMed ID: 25582384
[TBL] [Abstract][Full Text] [Related]
32. Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.
Ustun C; DeRemer DL; Akin C
Leuk Res; 2011 Sep; 35(9):1143-52. PubMed ID: 21641642
[TBL] [Abstract][Full Text] [Related]
33. Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs.
Aichberger KJ; Gleixner KV; Mirkina I; Cerny-Reiterer S; Peter B; Ferenc V; Kneidinger M; Baumgartner C; Mayerhofer M; Gruze A; Pickl WF; Sillaber C; Valent P
Blood; 2009 Dec; 114(26):5342-51. PubMed ID: 19850739
[TBL] [Abstract][Full Text] [Related]
34. The prognostic impact of c-KIT mutation in systemic mastocytosis associated with acute myeloid leukaemia patients.
Won D; Chi HS; Shim H; Jang S; Park CJ; Lee JH
Leuk Res; 2013 Aug; 37(8):883-8. PubMed ID: 23683787
[TBL] [Abstract][Full Text] [Related]
35. Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay.
Kristensen T; Vestergaard H; Møller MB
J Mol Diagn; 2011 Mar; 13(2):180-8. PubMed ID: 21354053
[TBL] [Abstract][Full Text] [Related]
36. Adverse Prognostic Impact of the
Naumann N; Lübke J; Baumann S; Schwaab J; Hoffmann O; Kreil S; Dangelo V; Reiter L; Bugert P; Kristensen T; Sotlar K; Haselmann V; Schneider S; Metzgeroth G; Weiss C; Popp HD; Fabarius A; Hofmann WK; Cross NCP; Reiter A; Jawhar M
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33806359
[TBL] [Abstract][Full Text] [Related]
37. The FIP1L1-PDGFRA fusion gene and the KIT D816V mutation are coexisting in a small subset of myeloid/lymphoid neoplasms with eosinophilia.
Schmitt-Graeff AH; Erben P; Schwaab J; Vollmer-Kary B; Metzgeroth G; Sotlar K; Horny HP; Kreipe HH; Fisch P; Reiter A
Blood; 2014 Jan; 123(4):595-7. PubMed ID: 24458279
[No Abstract] [Full Text] [Related]
38. Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis.
Lyberg K; Ali HA; Grootens J; Kjellander M; Tirfing M; Arock M; Hägglund H; Nilsson G; Ungerstedt J
Oncotarget; 2017 Feb; 8(6):9647-9659. PubMed ID: 28038453
[TBL] [Abstract][Full Text] [Related]
39. Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group.
Hoermann G; Sotlar K; Jawhar M; Kristensen T; Bachelot G; Nedoszytko B; Carter MC; Horny HP; Bonadonna P; Sperr WR; Hartmann K; Brockow K; Lyons JJ; Kluin-Nelemans HC; Hermine O; Akin C; Broesby-Olsen S; Triggiani M; Butterfield JH; Schwaab J; Reiter A; Gotlib J; Metcalfe DD; George TI; Orfao A; Valent P; Arock M
J Allergy Clin Immunol Pract; 2022 Aug; 10(8):1953-1963. PubMed ID: 35283331
[TBL] [Abstract][Full Text] [Related]
40. A new humanized in vivo model of KIT D816V+ advanced systemic mastocytosis monitored using a secreted luciferase.
Bibi S; Zhang Y; Hugonin C; Mangean MD; He L; Wedeh G; Launay JM; Van Rijn S; Würdinger T; Louache F; Arock M
Oncotarget; 2016 Dec; 7(50):82985-83000. PubMed ID: 27783996
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
